Enovis Co. (NYSE:ENOV) Position Increased by Victory Capital Management Inc.

Victory Capital Management Inc. raised its position in Enovis Co. (NYSE:ENOV) by 14.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,846 shares of the company’s stock after purchasing an additional 4,099 shares during the quarter. Victory Capital Management Inc.’s holdings in Enovis were worth $1,414,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of ENOV. River Road Asset Management LLC bought a new stake in shares of Enovis in the 3rd quarter valued at approximately $51,341,000. American Century Companies Inc. increased its stake in shares of Enovis by 78.6% during the 2nd quarter. American Century Companies Inc. now owns 1,511,871 shares of the company’s stock worth $68,337,000 after purchasing an additional 665,208 shares during the last quarter. Magnetar Financial LLC raised its holdings in shares of Enovis by 66.7% during the 2nd quarter. Magnetar Financial LLC now owns 1,104,803 shares of the company’s stock valued at $49,937,000 after purchasing an additional 442,051 shares in the last quarter. Diamond Hill Capital Management Inc. lifted its stake in shares of Enovis by 14.5% in the 2nd quarter. Diamond Hill Capital Management Inc. now owns 2,786,034 shares of the company’s stock valued at $125,929,000 after purchasing an additional 352,116 shares during the last quarter. Finally, Boston Partners boosted its holdings in Enovis by 206.5% in the first quarter. Boston Partners now owns 295,969 shares of the company’s stock worth $18,455,000 after purchasing an additional 199,411 shares in the last quarter. 98.45% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Needham & Company LLC restated a “buy” rating and set a $65.00 target price on shares of Enovis in a report on Thursday, November 7th. Evercore ISI reduced their target price on Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a report on Tuesday, October 1st. JMP Securities started coverage on Enovis in a report on Thursday, October 3rd. They set an “outperform” rating and a $62.00 price target on the stock. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Enovis from $53.00 to $50.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Enovis presently has an average rating of “Moderate Buy” and an average price target of $67.00.

Enovis Stock Up 3.4 %

Shares of ENOV stock opened at $48.27 on Tuesday. Enovis Co. has a 12 month low of $38.27 and a 12 month high of $65.03. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The firm has a market cap of $2.70 billion, a PE ratio of -21.84 and a beta of 1.91. The stock has a 50 day moving average of $42.70 and a 200-day moving average of $44.92.

Enovis (NYSE:ENOV) last released its earnings results on Wednesday, November 6th. The company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.62 by $0.11. The firm had revenue of $505.22 million during the quarter, compared to analysts’ expectations of $504.44 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The business’s quarterly revenue was up 21.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.56 EPS. On average, equities analysts predict that Enovis Co. will post 2.79 EPS for the current year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.